NASDAQ:SCPH scPharmaceuticals (SCPH) Stock Price, News & Analysis → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free SCPH Stock Alerts $5.49 -0.34 (-5.83%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$5.46▼$5.9550-Day Range$4.90▼$6.3552-Week Range$4.63▼$12.75Volume193,030 shsAverage Volume237,665 shsMarket Capitalization$197.91 millionP/E RatioN/ADividend YieldN/APrice Target$19.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get scPharmaceuticals alerts: Email Address scPharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside252.2% Upside$19.33 Price TargetShort InterestBearish20.53% of Float Sold ShortDividend StrengthN/ASustainability-0.88Upright™ Environmental ScoreNews Sentiment0.71Based on 16 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.26) to ($0.50) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.75 out of 5 starsMedical Sector262nd out of 947 stocksPharmaceutical Preparations Industry121st out of 435 stocks 3.5 Analyst's Opinion Consensus RatingscPharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $19.33, scPharmaceuticals has a forecasted upside of 252.2% from its current price of $5.49.Amount of Analyst CoveragescPharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted20.53% of the float of scPharmaceuticals has been sold short.Short Interest Ratio / Days to CoverscPharmaceuticals has a short interest ratio ("days to cover") of 19.8, which indicates bearish sentiment.Change versus previous monthShort interest in scPharmaceuticals has recently increased by 3.01%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldscPharmaceuticals does not currently pay a dividend.Dividend GrowthscPharmaceuticals does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorescPharmaceuticals has received a 65.04% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physiological diseases " product. See details.Environmental SustainabilityThe Environmental Impact score for scPharmaceuticals is -0.88. Previous Next 3.2 News and Social Media Coverage News SentimentscPharmaceuticals has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for scPharmaceuticals this week, compared to 1 article on an average week.Search Interest3 people have searched for SCPH on MarketBeat in the last 30 days. MarketBeat Follows2 people have added scPharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, scPharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.68% of the stock of scPharmaceuticals is held by insiders.Percentage Held by Institutions79.60% of the stock of scPharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for scPharmaceuticals are expected to grow in the coming year, from ($1.26) to ($0.50) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of scPharmaceuticals is -3.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of scPharmaceuticals is -3.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioscPharmaceuticals has a P/B Ratio of 2.60. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Monument Traders AllianceMake This $3 Trade the Instant the Opening Bell RingsSince the birth of Wall Street, one simple rule has remained the same.... Buy stocks that are cheap....When they’re on sale…. And when nobody else is looking…See Why This $3.00 Stock Could Hit $15.00 About scPharmaceuticals Stock (NASDAQ:SCPH)scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. for development of single use SmartDose device. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.Read More SCPH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SCPH Stock News HeadlinesMarch 18, 2024 | americanbankingnews.comResearch Analysts Offer Predictions for scPharmaceuticals Inc.'s FY2028 Earnings (NASDAQ:SCPH)March 18, 2024 | americanbankingnews.comFY2026 EPS Estimates for scPharmaceuticals Inc. (NASDAQ:SCPH) Lifted by Leerink PartnrsMarch 18, 2024 | Monument Traders Alliance (Ad)Make This $3 Trade the Instant the Opening Bell RingsSince the birth of Wall Street, one simple rule has remained the same.... Buy stocks that are cheap....When they’re on sale…. And when nobody else is looking…March 16, 2024 | insidermonkey.comscPharmaceuticals Inc. (NASDAQ:SCPH) Q4 2023 Earnings Call TranscriptMarch 16, 2024 | finance.yahoo.comSCPH Apr 2024 5.000 putMarch 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for scPharmaceuticals Amidst Revenue Surge and Solid Financial FootingMarch 14, 2024 | finance.yahoo.comQ4 2023 scPharmaceuticals Inc Earnings CallMarch 14, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Neurocrine (NBIX), Jazz Pharmaceuticals (JAZZ) and scPharmaceuticals (SCPH)March 18, 2024 | Monument Traders Alliance (Ad)Make This $3 Trade the Instant the Opening Bell RingsSince the birth of Wall Street, one simple rule has remained the same.... Buy stocks that are cheap....When they’re on sale…. And when nobody else is looking…March 14, 2024 | markets.businessinsider.comStrong Buy Recommendation for scPharmaceuticals on Furoscix’s Successful Launch and Growth ProspectsMarch 13, 2024 | finance.yahoo.comscPharmaceuticals Inc (SCPH) Reports Q4 and Full-Year 2023 Financials, Focusing on FUROSCIX GrowthMarch 13, 2024 | globenewswire.comscPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business UpdateMarch 12, 2024 | msn.comscPharmaceuticals Q4 2023 Earnings PreviewMarch 11, 2024 | markets.businessinsider.comCraig-Hallum Reaffirms Their Buy Rating on scPharmaceuticals (SCPH)March 11, 2024 | americanbankingnews.comscPharmaceuticals (SCPH) to Release Quarterly Earnings on WednesdayMarch 9, 2024 | markets.businessinsider.comscPharmaceuticals Inc Registered Shs hosts conference call for investorsMarch 6, 2024 | globenewswire.comscPharmaceuticals to Announce Fourth Quarter and Full-Year 2023 Financial Results on Wednesday, March 13, 2024February 28, 2024 | globenewswire.comscPharmaceuticals to Participate in Two Upcoming Investor ConferencesFebruary 21, 2024 | benzinga.comscPharmaceuticals Stock (NASDAQ:SCPH), Short Interest ReportJanuary 15, 2024 | finanznachrichten.deDelveInsight Business Research, LLP: Heart Failure Treatment Drug Market to Accelerate Immensely by 2032, Predicts DelveInsightJanuary 8, 2024 | msn.comTop 10 stocks with the highest short interest on Wall StreetJanuary 7, 2024 | markets.businessinsider.comStrong Buy: scPharmaceuticals’ Furoscix Shows Robust Sales Growth and Solid Financial HealthJanuary 5, 2024 | markets.businessinsider.comBuy Rating for scPharmaceuticals: Furoscix’s Market Traction and Growth Potential Drive Positive ValuationJanuary 5, 2024 | finanznachrichten.descPharmaceuticals, Inc.: scPharmaceuticals Announces Preliminary Unaudited Q4 and Full-Year 2023 Net FUROSCIX RevenueJanuary 4, 2024 | finance.yahoo.comscPharmaceuticals Announces Preliminary Unaudited Q4 and Full-Year 2023 Net FUROSCIX® RevenueJanuary 3, 2024 | markets.businessinsider.comPinstripes, SoFi Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market SessionDecember 23, 2023 | msn.comVYGR, VSAT and SNBR are among after hour moversSee More Headlines Receive SCPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for scPharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2021Today3/18/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SCPH CUSIPN/A CIK1604950 Webwww.scpharma.com Phone(617) 517-0730FaxN/AEmployees96Year FoundedN/APrice Target and Rating Average Stock Price Target$19.33 High Stock Price Target$20.00 Low Stock Price Target$18.00 Potential Upside/Downside+252.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-36,840,000.00 Net MarginsN/A Pretax Margin-403.22% Return on Equity-97.18% Return on Assets-49.59% Debt Debt-to-Equity Ratio1.04 Current Ratio7.08 Quick Ratio8.88 Sales & Book Value Annual Sales$13.59 million Price / Sales14.56 Cash FlowN/A Price / Cash FlowN/A Book Value$2.11 per share Price / Book2.60Miscellaneous Outstanding Shares36,050,000Free Float34,182,000Market Cap$197.91 million OptionableOptionable Beta0.08 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. John H. Tucker (Age 61)President, CEO, Principal Executive Officer & Director Comp: $912.2kMs. Rachael Nokes (Age 49)CFO & Principal Accounting Officer Comp: $496.45kMr. Michael D. HassmanSenior Vice President of Technical OperationsKatherine TaudvinVice President of Corporate Affairs & Human ResourcesDr. John Mohr Pharm.D.Senior Vice President of Clinical Development & Medical AffairsSteve ParsonsSenior Vice President of CommercialMore ExecutivesKey CompetitorsXBiotechNASDAQ:XBITVaccitechNASDAQ:VACCCorMedixNASDAQ:CRMDTrevi TherapeuticsNASDAQ:TRVIOvid TherapeuticsNASDAQ:OVIDView All CompetitorsInstitutional OwnershipVanguard Group Inc.Bought 150,871 shares on 3/11/2024Ownership: 3.820%Goldman Sachs Group Inc.Bought 24,302 shares on 3/1/2024Ownership: 0.126%Barclays PLCBought 34,563 shares on 2/15/2024Ownership: 0.111%Wolverine Trading LLCBought 7,726 shares on 2/15/2024Ownership: 0.055%Citadel Advisors LLCBought 10,000 shares on 2/15/2024Ownership: 0.000%View All Institutional Transactions SCPH Stock Analysis - Frequently Asked Questions Should I buy or sell scPharmaceuticals stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for scPharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SCPH shares. View SCPH analyst ratings or view top-rated stocks. What is scPharmaceuticals' stock price target for 2024? 2 Wall Street analysts have issued 12-month price objectives for scPharmaceuticals' stock. Their SCPH share price targets range from $18.00 to $20.00. On average, they anticipate the company's stock price to reach $19.33 in the next year. This suggests a possible upside of 252.2% from the stock's current price. View analysts price targets for SCPH or view top-rated stocks among Wall Street analysts. How have SCPH shares performed in 2024? scPharmaceuticals' stock was trading at $6.27 at the start of the year. Since then, SCPH stock has decreased by 12.4% and is now trading at $5.49. View the best growth stocks for 2024 here. When is scPharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our SCPH earnings forecast. How were scPharmaceuticals' earnings last quarter? scPharmaceuticals Inc. (NASDAQ:SCPH) released its quarterly earnings results on Tuesday, November, 9th. The company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.07. What guidance has scPharmaceuticals issued on next quarter's earnings? scPharmaceuticals issued an update on its fourth quarter 2023 earnings guidance on Thursday, January, 4th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $5.9 million-$6.1 million, compared to the consensus revenue estimate of $5.3 million. What other stocks do shareholders of scPharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other scPharmaceuticals investors own include Adamas Pharmaceuticals (ADMS), Dynavax Technologies (DVAX), Fulcrum Therapeutics (FULC), ImmunoGen (IMGN), VBI Vaccines (VBIV), Selecta Biosciences (SELB), SCYNEXIS (SCYX), Syndax Pharmaceuticals (SNDX), Sorrento Therapeutics (SRNE) and TG Therapeutics (TGTX). When did scPharmaceuticals IPO? (SCPH) raised $96 million in an initial public offering (IPO) on Friday, November 17th 2017. The company issued 6,400,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO. Who are scPharmaceuticals' major shareholders? scPharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Rubric Capital Management LP (9.76%), AIGH Capital Management LLC (8.66%), King Luther Capital Management Corp (3.89%), Vanguard Group Inc. (3.82%), Vanguard Group Inc. (3.82%) and Worth Venture Partners LLC (2.15%). Insiders that own company stock include 5Am Partners Iv, Llc, Jack A Khattar, John H Tucker and Orbimed Advisors Llc. View institutional ownership trends. How do I buy shares of scPharmaceuticals? Shares of SCPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SCPH) was last updated on 3/18/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial MetalsLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceStock-Picking AI Predicts #1 Stock of 2024AltimetryDid you make $29,000 two days with AI options trades?Prosper Trading AcademyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding scPharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.